Chemical compound
Pharmaceutical compound
Iohexol Clinical data Trade names Iodaque, Hexopaque, Oraltag, others Other names 5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide AHFS /Drugs.com Micromedex Detailed Consumer Information License data Routes of Intrathecal ,intravascular ,by mouth , intracavital,rectal ATC code Legal status Legal status Pharmacokinetic dataProtein binding Low Metabolism Nil Eliminationhalf-life Variable Excretion Kidney , unchangedIdentifiers 1-N ,3-N -Bis(2,3-dihydroxypropyl)-5-[N -(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number PubChem CID DrugBank ChemSpider UNII KEGG ChEBI ChEMBL CompTox Dashboard (EPA) ECHA InfoCard 100.060.130 Chemical and physical data Formula C 19 H 26 I 3 N 3 O 9 Molar mass −1 3D model (JSmol ) Melting point 174 to 180 °C (345 to 356 °F) InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)
Y Key:NTHXOOBQLCIOLC-UHFFFAOYSA-N
Y N Y (what is this?) (verify)
Iohexol , sold under the trade nameIodaque among others, is acontrast agent used forX-ray imaging .[ 4] arteries ,veins ,ventricles of the brain , theurinary system , andjoints , as well as duringcomputed tomography (CT scan).[ 4] injection into a vein , or into a body cavity.[ 5]
Side effects includevomiting ,skin flushing , headache, itchiness,kidney problems , andlow blood pressure .[ 4] allergic reactions orseizures may occur.[ 4] povidone-iodine orshellfish do not affect the risk of side effects more than other allergies.[ 6] pregnancy may causehypothyroidism in the baby.[ 7] iodinated non-ionic radiocontrast agent .[ 4] osmolar family.[ 8]
Iohexol was approved for medical use in 1985.[ 9] World Health Organization's List of Essential Medicines .[ 10] [ 5]
Theosmolality of iohexol ranges from 322mOsm /kg—approximately 1.1 times that ofblood plasma —to 844 mOsm/kg, almost three times that of blood.[ 11] diatrizoate , may be more than twice as high.[ 12]
The most common side effects after intravenous injections are: pain at the site of injection (3%), blurring of vision (2%), nausea (2%), arrhythmia (2%), taste perversion (1%), hypotension (0.7%), and vomiting (0.7%).[ 13]
Society and culture [ edit ] It is sold under the brand name Omnipaque.[ 14] [ 15] [ 16]
It is available in various concentrations, from 140[ 13] [ 17] milligrams ofiodine permilliliter .[ 13] [ 13]
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)" .nctr-crs.fda.gov .FDA . Retrieved22 October 2023 .^ "Product monograph brand safety updates" .Health Canada . February 2024. Retrieved24 March 2024 .^ "Regulatory Decision Summary for Omnipaque" .Drug and Health Products Portal . 29 December 2023. Retrieved2 April 2024 .^a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.).WHO Model Formulary 2008 . World Health Organization. pp. 317– 8.hdl :10665/44053 ISBN 9789241547659 ^a b Hamilton R (2015).Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition . Jones & Bartlett Learning. p. 171.ISBN 9781284057560 ^ ACR Manual on Contrast Media v10.3. 2017 (PDF) . American College of Radiology. 2017. p. 6.ISBN 9781559030120 Archived (PDF) from the original on 1 January 2018. Retrieved1 January 2018 .^ Briggs GG, Freeman RK, Yaffe SJ (2011).Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk ISBN 9781608317080 Archived from the original on 1 January 2017. ^ Sutton D, Young JW (2012).A Short Textbook of Clinical Imaging ISBN 9781447117551 Archived from the original on 1 January 2017. ^ Broe ME, Porter GA, Bennett WM, Verpooten GA (2013).Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals ISBN 9789401590884 Archived from the original on 1 January 2017. ^ World Health Organization (2019).World Health Organization model list of essential medicines: 21st list 2019 . Geneva: World Health Organization.hdl :10665/325771 ^ GE Healthcare (May 2006)."Omnipaque (Iohexol) injection. Product label" .DailyMed . U.S.National Library of Medicine . Retrieved28 March 2007 .^ Amersham Health (April 2006)."Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label" .DailyMed . U.S.National Library of Medicine .Archived from the original on 23 May 2011. Retrieved29 March 2007 . ^a b c d "Highlights of prescribing information for Omnipaque" (PDF) . US Food and Drug Administration. Archived fromthe original (PDF) on 11 July 2022. Retrieved13 December 2022 .^ "Omnipaque" (PDF) . Ireland: Health Products Regulatory Authority. January 2018. Retrieved31 July 2020 .^ "HistoDenz" (PDF) .Product information sheet . Sigma-Aldrich. D2158. Archived fromthe original (PDF) on 20 November 2015. Retrieved19 November 2015 .^ "Nycodenz®: A universal density gradient medium" (PDF) . Axis-Shield Density Gradient Media. Archived fromthe original (PDF) on 26 February 2015. Retrieved19 November 2015 .^ Haberfeld H, ed. (2020).Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Omnipaque 350 mg J/ml Infusionsflasche.
N
Y (what is this?) (verify)